Sender's message:
Sent on Saturday, 2011 Sep 24
Search angiotensin cancer
| PubMed Results |
| Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins. | |
| Cancer Invest. 2011 Sep 21. [Epub ahead of print] | |
| PMID: 21936625 [PubMed - as supplied by publisher] | |
Young Kwang Chae,1,2,§ Matias E. Valsecchi,2,3,§ Jongoh Kim,2,4 Anabella Lucca Bianchi,2 Danai Khemasuwan,2,5 Ajit Desai,2 and William Tester,2
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,1
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA,2
Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA,3
Department of Medicine, Balyor College of Medicine, Houston, TX, USA,4
Department of Medicine, Cleveland Clinic, Cleveland, OH, USA5
Background:
Epidemiologic and biochemical evidence suggest a role of statins and
angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor
blockers (ARBs) as anti-neoplastic agents. This study was designed to
evaluate the association between the use of these agents and the risk of
breast cancer recurrence. Methods: We reviewed the medical
records of patients treated for stage II/III breast cancer between 1999
and 2005. Statin and ACE-inhibitors/ARB users were defined as patients
who took these medications for at least 6 months in no evidence of
disease (NED) stage after the initial diagnosis. The primary outcome was
disease-free survival and the secondary was overall survival. The
Kaplan–Meier and Cox proportional hazard models were used. Results:
A total of 703 patients were included. The median and maximal of follow
up was 55 and 118 months, respectively. A total of 168 patients used
ACE-inhibitors/ARBs, 156 patients used statins, and 81 used both.
Univariate analysis showed significant reduction in breast cancer
recurrence among patients who used ACE-inhibitors/ARBs (hazard ratio
(HR) = 0.57; 95% CI: 0.37–0.89; p = .013) or statins (HR = 0.43; 95% CI: 0.26–0.70; p < .001). After adjusting for multiple variables, the use of ACE-inhibitors/ARBs (HR = 0.49; 95% CI: 0.31–0.76; p = .002) and statins (HR = 0.40; 95% CI: 0.24–0.67; p < .001) remained significant and an additive effect was found on those who used both drugs (HR = 0.30 95% CI: 0.15–0.61; p = .001). No association was found regarding overall survival. Conclusions:
The use of ACE-inhibitors/ARBs, statins, and the combination of both
were all associated with a reduced risk of breast cancer recurrence.
This observation should prompt further exploration.
Read More: http://informahealthcare.com/doi/abs/10.3109/07357907.2011.616252 |
Nenhum comentário:
Postar um comentário